THE WHAT? Cosmo Pharmaceuticals’ share price jumped 24% after the company reported statistically significant outcomes from two late-stage trials of its experimental male hair loss treatment.
THE DETAILS The Switzerland-listed company announced that its clascoterone cream achieved major efficacy milestones in both Phase III studies. In one trial, patients recorded a 539% relative improvement in target-area hair count compared with placebo, while the second reported a 168% improvement. These findings represent the strongest clinical performance the company has disclosed to date.
The update drove Cosmo’s largest single-day share rise since 2008, reflecting renewed investor confidence in the company’s dermatology pipeline. Analysts at Oddo BHF estimate that, if approved, the treatment could compete in a global hair loss therapeutics market valued in the billions.
THE WHY? Breakthrough clinical data in a high-demand category such as male hair loss strengthens Cosmo’s commercial outlook and positions clascoterone as a potential entrant in a rapidly expanding global market.
Source: Bloomberg , Cosmo Pharmaceuticals
The post Cosmo Pharmaceuticals Shares Surge After Male Hair Loss Treatment Delivers Breakthrough Phase III Results appeared first on Global Cosmetics News.